Cardioncology, oncocardiology. Are we barking up the wrong tree?

International Journal of Cardiology

Volumn 167, Issue 2, 2013, Pages 307-309

  Lestuzzi, C ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Antineoplastic therapies; Cardioncology; Cardiotoxicity; Fluoropyrimidines; Oncocardiology; Radiation heart disease

Indexed keywords

AMIODARONE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CAPECITABINE; CYTOCHROME P450 3A4; DASATINIB; FLECAINIDE; FLUOROURACIL; IBUTILIDE; NILOTINIB; PROPAFENONE; PROTEIN TYROSINE KINASE INHIBITOR; QUINIDINE; RANOLAZINE; SOTALOL; SUNITINIB; TRASTUZUMAB; VASCULOTROPIN INHIBITOR;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; BREAST CANCER; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CONVALESCENCE; DRUG METABOLISM; EVENT FREE SURVIVAL; HEART ARRHYTHMIA; HEART CANCER; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART LYMPHOMA; HEART METASTASIS; HEART PROTECTION; HEART SARCOMA; HEART SURGERY; HEART VENTRICLE ARRHYTHMIA; HODGKIN DISEASE; HUMAN; HYPERTENSION; INCIDENCE; LUNG EMBOLISM; MALIGNANT NEOPLASTIC DISEASE; NONHODGKIN LYMPHOMA; PATIENT MONITORING; PATIENT SELECTION; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; SUDDEN DEATH; THROMBOEMBOLISM; TREATMENT PLANNING; VASCULITIS;

EID: 84879116280     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.04.148     Document Type: Editorial

References (35)

1. C. Todaro, L. Oreto, R. Qamar, T.E. Ptherick, S. Carerj, and B.K. Khandheria Cardioncology: state of the heart review Int J Cardiol 2013 10.1016/j.ijcard.2013.03.133
2. F.G. Bakaeen, D.E. Jaroszewski, and D.C. Rice Outcomes after surgical resection of cardiac sarcoma in the multimodality treatment era J Thorac Cardiovasc Surg 137 2009 1454 1460
3. M. Leja, and M.J. Reardon Cardiac sarcomas: therapeutic options? Future Cardiol 7 2011 595 597
4. C. Lestuzzi, G. Miolo, and A. De Paoli Systemic therapy, radiotherapy and cardiotoxicity C. Basso, M. Valente, G. Thiene, Cardiac Tumor Pathology 2013 Humana Press New York 165 182
5. C. Lestuzzi Neoplastic pericardial disease: old and current strategies for diagnosis and management World J Cardiol. 2 2010 270 279
6. C. Lestuzzi, A. Bearz, and C. Lafaras Neoplastic pericardial disease in lung cancer: impact on outcomes of different treatment strategies. A multicenter study Lung Cancer 72 2011 340 347
7. F. Dammacco, A. Vacca, P. Procaccio, R. Ria, I. Marech, and V. Racanelli Cancer-related coagulopathy (Trousseau's syndrome): review of the literature and experience of a single center of internal medicine Clin Exp Med. 13 2 2013 May 85 97
8. G. Piazza, A.F. Rao, and T.N. Nguyen Venous thromboembolism in hospitalized patients with active cancer Clin Appl Thromb Hemost. 2013 March 11
9. G. Curigliano, D. Cardinale, and T. Suter ESMO Guidelines Working Group Ann Oncol 23 Suppl. 7 2012 vii155 vii166
10. C. Schöber, E. Papageorgiou, and A. Harstrick Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer Cancer 72 1993 2242 2247
11. C. Kosmas, M.S. Kallistratos, and P. Kopterides Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study J Cancer Res Clin Oncol 134 2008 75 82
12. M. Wasif Saif, M.M. Shah, and A.R. Shah Fluoropyrimidine-associated cardiotoxicity: revisited Expert Opin Drug Saf 8 2009 191 202
13. M.F. Sorrentino, J. Kim, A.E. Foderaro, and A.G. Truesdell 5-fluorouracil induced cardiotoxicity: review of the literature Cardiol J 19 2012 453 458 [Review]
14. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11 30
15. R.A. Goodwin, and T.R. Asmis Overview of systemic therapy for colorectal cancer Clin Colon Rectal Surg. 22 2009 251 256
16. A. Argiris Current status and future directions in induction chemotherapy for head and neck cancer Crit Rev Oncol Hematol Mar 27 2013 10.1016/j.critrevonc.2013.03.001
17. J.A. O'Shaughnessy, M. Kaufmann, and F. Siedentopf Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer Oncologist 7 2012 476 484
18. S.C. Darby, M. Ewertz, and P. McGale Risk of ischemic heart disease in women after radiotherapy for breast cancer N Engl J Med 368 11 Mar 14 2013 987 998
19. M.C. Hull, C.G. Morrid, C.J. Pepine, and N.P. Mendenhall Valvular dysfunction and carotid, subclavian, and coronary artery disese in survivors of Hodgkin Lymphoma treated with radiation therapy JAMA 290 2003 2831 2837
20. K.A. Copeland, V.R. Hosmane, and C. Jurkovitz Frequency of severe valvular disease caused by mediastinal radiation among patients undergoing valve surgery in a community-based, regional academic medical center Clin Cardiol Mar 14 2013 [Electronic publication ahead of print]
21. S.L. Galper, J.B. Yu, and P.M. Mauch Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation Blood 117 2011 412 418
22. B.M. Aleman, A.W. van den Belt-Dusebout, and M.L. De Bruin Late cardiotoxicity after treatment for Hodgkin lymphoma Blood 109 2007 1878 1886
23. P.A. Heidenreich, I. Schnittger, and H.W. Strauss Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease J Clin Oncol 25 2007 43 49 Erratum in: J Clin Oncol 2007;25:1635
24. E.M. van Leeuwen-Segarceanu, W.J. Bos, and L.D. Dorresteijn Screening Hodgkin lymphoma survivors for radiotherapy induced cardiovascular disease Cancer Treat Rev 37 2011 391 403
25. D.C. Hodgson Late effects in the era of modern therapy for Hodgkin lymphoma Hematology Am Soc Hematol Educ Program. 2011 2011 323 329
26. B.S. Hoppe, S. Flampouri, and Z. Su Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma Int J Radiat Oncol Biol Phys 84 2012 449 455
27. J. Clavel, E. Steliarova-Foucher, C. Berger, S. Danon, and Z. Valerianova Hodgkin's disease incidence and survival in European children and adolescents (1978-1997): report from the Automated Cancer Information System project Eur J Cancer 42 2006 2037 2049
28. M. Sant, C. Allemani, C. Tereanu, R. De Angelis, R. Capocaccia, and O. Visser HAEMACARE Working Group. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project Blood 116 19 Nov 11 2010 3724 3734
29. H. Hjalgrim, J. Askling, E. Pukkala, S. Hansen, L. Munksgaard, and M. Frisch Incidence of Hodgkin's disease in Nordic countries Lancet 358 2001 297 298
30. L.M. Morton, S.S. Wang, S.S. Devesa, P. Hartge, D.D. Weisenburger, and M.S. Linet Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001 Blood 107 2006 265 276
31. R.M. Steingart, G.L. Bakris, and H.X. Chen Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors Am Heart J 163 2012 156 163
32. B.B. Hasinoff, and D. Patel The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro Toxicol Appl Pharmacol 249 2010 132 139
33. P. Di Gion, F. Kanefendt, and A. Lindauer Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles Clin Pharmacokinet 50 2011 551 603
34. D.A. Flockhart Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine http://medicine.iupui.edu/clinpharm/ddis/ table.aspx 2007 [Accessed March 31st 2013]
35. Truven Health Analytics Inc.; Micromedex 2.0 DrugPoint. Accessed April 2nd, 2013.